Androgen receptor expression and breast cancer survival in postmenopausal women.
Androgen receptor expression and breast cancer survival in postmenopausal women.
复制标题
绝经后妇女的雄激素受体表达和乳腺癌存活。
DOI：
10.1158/1078-0432.ccr-10-2021
复制
发表时间：
2011-04-01
期刊：
影响因子：
--
通讯作者：
Tamimi RM
中科院分区：
文献类型：
--
作者：
Hu R;Dawood S;Holmes MD;Collins LC;Schnitt SJ;Cole K;Marotti JD;Hankinson SE;Colditz GA;Tamimi RM
雄激素受体（AR）通常在乳腺癌中表达。然而，肿瘤AR状态与乳腺癌生存率之间的关系尚不确定。因此，我们在护士健康研究（NHS）中研究了AR状态与乳腺癌生存率之间的关系。这是一项前瞻性研究，研究对象为1976年至1997年期间诊断为I至III期乳腺癌的绝经后女性，这些女性参加了护士健康研究（NHS），并从诊断之日起随访至2008年1月1日或死亡。使用Kaplan-Meier方法和考克斯比例风险模型进行分析，以确定AR状态与校正协变量后的生存结局的相关性。在1467例乳腺癌中，78.7%为AR阳性（AR+）。在1,164例雌激素受体（ER）阳性病例中，88.0%为AR+。在调整协变量后，AR阳性与乳腺癌死亡率（风险比，0.68; 95%置信区间，0.47至0.99）和总死亡率（风险比，0.70; 95%置信区间，0.53至0.91）显著降低相关。相比之下，在ER阴性肿瘤的女性（303例）中，42.9%为AR+。AR状态与乳腺癌死亡之间无显著相关性（风险比，1.59; 95%置信区间，0.94 - 2.68）。AR状态与乳腺癌生存率的相关性取决于ER状态。特别是，AR表达与ER阳性肿瘤患者的预后更好相关。因此，AR状态的测定可能为绝经后乳腺癌妇女的预后提供额外的信息，并为靶向治疗提供新的机会。
Androgen receptor (AR) is commonly expressed in breast cancers. However, the association between tumor AR status and breast cancer survival is uncertain. Hence, we examined the association between AR status and breast cancer survival in the Nurses’ Health Study (NHS). It was a prospective study of postmenopausal women enrolled in the Nurses’ Health Study (NHS) with stage I to III breast cancer diagnosed between 1976 and 1997 and followed from the date of diagnosis until January 1, 2008 or death. Analyses were conducted using Kaplan-Meier methods and Cox proportional hazard models, to determine the association of AR status with survival outcomes adjusting for covariates. Among 1467 breast cancers, 78.7% were AR-positive (AR+). Among 1,164 estrogen receptor (ER)-positive cases, 88.0% were AR+. AR positivity was associated with a significant reduction in breast cancer mortality (hazard ratio, 0.68; 95 percent confidence interval, 0.47 to 0.99) and overall mortality (hazard ratio, 0.70; 95 percent confidence interval, 0.53 to 0.91) after adjustment for covariates. In contrast, among women with ER-negative tumors (303 cases), 42.9% were AR+. There was a non-significant association between AR status and breast cancer death (hazard ratio, 1.59; 95 percent confidence interval, 0.94 to 2.68). The association of AR status and breast cancer survival is dependent on ER status. In particular, AR expression was associated with a more favorable prognosis among women with ER-positive tumors. Thus, determination of AR status may provide additional information on prognosis for postmenopausal women with breast cancer, and provide novel opportunities for targeted therapy.